ZURICH:Britain on Wednesday became the first country to approve AstraZeneca and Oxford University's home-grown UK COVID-19 vaccine, adding an easy-to-manage shot to the arsenal of a nation desperate for pandemic relief.
Even so, scientists - and regulators in Europe, following the Brexit divorce - are sceptical, given confusion over trial results earlier that left experts questioning the robustness of the data.
HOW DOES THE ASTRAZENECA SHOT'S EFFICACY STACK UP TO OTHERS'?
The AstraZeneca/Oxford vaccine's efficacy in preventing symptomatic infections was 70.4%, according to interim data, after 30 of 5,807 people who got the two-dose vaccine developed COVID-19, compared with 101 of 5,829 people who got a placebo.
That compares with the 95% efficacy of the two-shot vaccine from Pfizer/BioNTech, the other vaccine approved in Britain.
While efficacy with any dose after one dose was pegged at 52.7%, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regulator also said an "exploratory analysis" of trial participants who got one full dose showed efficacy of 73% from 22 days after the first shot.
The UK regulator recommends a booster shot four to 12 weeks after the first dose, because up to 80% efficacy was reached with a three-month interval between shots, an official involved in the MHRA approval said.
"The first dose efficacy gives an indication of protection for a short period between the two doses, the second dose strengthens the immune response and is expected to provide a more durable immune response," the University of Oxford, AstraZeneca's partner, said.
Confusion over efficacy emerged after interim late-stage trial results announced in late November when AstraZeneca acknowledged that people in its clinical trial accidentally got different doses.
Those who received a half dose of the vaccine, followed by a full dose, were shown to have 90% protection, the company said initially, while two full doses offered only 62% protection.
Now, however, the MHRA said the half-dose regimen's results were not borne out in analysis.
"It's all much more confusing because mistakes have been made, genuinely," one European Medicines Agency (EMA) official told Reuters. "Mistakes that resulted in clinical data that was much more complex to interpret than Moderna's and Pfizer's. And on top of that the efficacy is lower."
WHAT ARE THE OTHER DIFFERENCES?
Technology, price and storage.
The AstraZeneca shot is a "viral vector vaccine", where a specially engineered virus that normally causes chimpanzees to get the common cold delivers genetic instructions to human cells to make the spike protein jutting out from the new coronavirus's surface.
The Pfizer/BioNTech and Moderna vaccines use a new technology which packs messenger RNA (mRNA) inside tiny fat droplets to instruct cells to make the spike protein.
AstraZeneca pledged the vaccine would cost just a few dollars per dose and be sold without making a profit, whereas Pfizer's vaccine costs $18.40-$19.50 per dose.
A separate mRNA vaccine from Moderna, approved in the United States, costs up to $37.
The AstraZeneca shot does not require deep freezing at minus 70 degrees like the mRNA vaccine from Pfizer and its German partner, BioNTech, and has already been produced by the millions of doses.
It can be kept in a standard refrigerator for six months.
It is also cheaper to make, bringing hope to developing countries largely left out of the early vaccine haul.
NOW THAT THE UK HAS APPROVED THE VACCINE, WILL OTHER GOVERNMENTS FOLLOW?
When Britain signed off on Pfizer/BioNTech's vaccine in early December, that pressured regulators elsewhere, and the United States and Europe followed in short order.
Moderna's similar mRNA vaccine has also received U.S. approval.
Britain's move now to back AstraZeneca's shot prioritises getting as many people inoculated quickly, before all the answers about efficacy and optimal dosing are in.
Absent safety concerns, British regulators may be making a trade-off between waiting for perfection and making do with what they have.
"A swift emergency approval implies taking the risks of a lower (or) shorter efficacy than may be reached with mRNA vaccines," said Claire-Anne Siegrist, vaccinology and immunology head at Geneva's University Hospitals.
While an EMA official said this week the shot is unlikely to be approved before the end of January, a top German vaccine official said on Wednesday he still expected a "quick decision" by Europe since its rolling review process is well advanced.
The EU drug watchdog is carrying out a review for a conditional market approval, rather than the UK's speedier emergency use approval.
India's drug regulator is also discussing emergency approval of the AstraZeneca vaccine, being made in partnership with the Serum Institute of India.
WHO WILL GET WHICH VACCINE?
England's National Health Service will not give people a choice of vaccine.
But with several now available, countries need to decide who should get which vaccine, as some people may prefer the shots with higher efficacy.
Experts said the differences between the efficacy rates are significant, prompting tough choices.
"In countries where both the mRNA and the AstraZeneca vaccines would be available, whom do you decide to give the less effective vaccine?" Siegrist said.
Thomas Mertens, head of STIKO, Germany's expert panel on vaccine use, told Reuters that his group plans to address this issue "in the near future" as it hopes to tailor a strategy that makes the biggest impact with limited supplies.
Some experts, however, said that choice may be a luxury countries cannot afford.
"At this juncture, we don't have vaccine in sufficient quantities to reach all those who need it," said Thomas Klimkait, a University of Basel professor and researcher who is working on a Swiss SARS-CoV-2 vaccine project.
"I would say at this moment that every vaccine with relatively good efficacy - that means, at least 60 or 70% - should be put to use, when it has an appropriate safety profile."
Reuters
Thu Dec 31 2020
The AstraZeneca/Oxford vaccine's efficacy in preventing symptomatic infections was 70.4%, according to interim data. - REUTERS
KPT mahu lahir ramai pakar dalam bidang kesihatan planet
Kerajaan bercadang untuk memberikan penekanan untuk menghasilkan graduan yang seterusnya menjadi pakar dalam bidang Planetary Health atau Kesihatan Planet di masa akan datang. Ketua Setiausaha Kementerian Pengajian Tinggi, Datuk Seri Zaini Ujang ketika ditemu bual Astro AWANI seusai memberikan ucapan bersempena penganjuran Sidang Kemuncak Kesihatan Planet (PHAM 2024) pada Khamis berkata, untuk menjayakan perkara itu dua kerangka perlu dilaksanakan.
Kadar miskin tegar di Johor rendah, mampu diatasi
Perdana Menteri, Datuk Seri Anwar Ibrahim berhasrat menoktahkan kadar kemiskinan tegar di Johor.
Katanya, Johor mencatat kadar kemiskinan tegar yang rendah iaitu kurang daripada 2,000 individu, dan mampu diselesaikan dalam masa yang singkat.
Katanya, Johor mencatat kadar kemiskinan tegar yang rendah iaitu kurang daripada 2,000 individu, dan mampu diselesaikan dalam masa yang singkat.
Google pecat 28 pekerja protes perjanjian pengkomputeran awan dengan Israel
Google memecat 28 pekerja yang mengambil bahagian dalam bantahan terhadap projek gergasi teknologi bernilai US$1.2 bilion untuk membekalkan perkhidmatan pengkomputeran awan kepada kerajaan Israel, Sputnik memetik laporan media AS pada Khamis.
Jepun dilanda gempa bumi, sembilan cedera
Sembilan orang dilaporkan cedera selepas gempa bumi berukuran 6.6 magnitud melanda barat daya Jepun, pada Khamis.
Peserta Freedom Flotilla to Gaza dari Malaysia tiba di Turki
Kesemua 19 peserta dari Malaysia yang menyertai misi Break the Siege of Gaza Freedom Flotilla tiba di Istanbul, Turkiye pada 2.47 petang Khamis (waktu tempatan).
Banjir di Melaka pulih sepenuhnya
Pusat pemindahan sementara (PPS) yang diaktifkan di Melaka bagi menempatkan mangsa banjir di beberapa kawasan di negeri itu ditutup sepenuhnya pada Khamis.
SKMM sita telefon bimbit milik tiga individu
Suruhanjaya Komunikasi dan Multimedia Malaysia (SKMM) telah menyita telefon bimbit milik ketiga-ketiga individu untuk memuat naik video bagi membantu siasatan.
SKMM turut merakam percakapan Badrul Hisham (Chegubard),Salim Iskandar di Ibu Pejabat MCMC di Cyberjaya, Selangor. Sementara, Wan Muhammad Azri bin Wan Deris (Papagomo) dilakukan di Balai Polis Setapak.
SKMM turut merakam percakapan Badrul Hisham (Chegubard),Salim Iskandar di Ibu Pejabat MCMC di Cyberjaya, Selangor. Sementara, Wan Muhammad Azri bin Wan Deris (Papagomo) dilakukan di Balai Polis Setapak.
Bas langgar 11 kenderaan, dua cedera
Hilang kawalan akibat kegagalan brek dipercayai punca sebuah bas melanggar 11 kenderaan lain di persimpangan lampu isyarat Jalan Tan Swee Hoe-Jalan Kluang di Batu Pahat, Johor.
Bekas juruteknik didakwa kali kedua
Seorang bekas juruteknik sekali lagi dihadapkan ke Mahkamah Sesyen Kuala Lumpur hari ini, atas pertuduhan membuat hantaran menghina agama Islam berkaitan isu penjualan stoking tertera kalimah Allah melalui Facebook miliknya, Mac lepas.
Penunggang motosikal maut tercampak 30 meter dari jejantas
Seorang penunggang motosikal maut selepas terjatuh dari ketinggian kira-kira 30 meter dalam kemalangan di Jejantas Sungai Tiram, Bayan Lepas petang Khamis.
Mangsa lelaki berusia 27 tahun itu dilaporkan meninggal dunia semasa mendapatkan rawatan di Zon Merah sebuah hospital swasta.
Mangsa lelaki berusia 27 tahun itu dilaporkan meninggal dunia semasa mendapatkan rawatan di Zon Merah sebuah hospital swasta.
AstraZeneca berjaya batalkan saman 12 individu berhubung isu suntikan vaksin COVID-19
Hakim Mahkamah Tinggi Dr Suzana Muhamad Said membenarkan permohonan Astrazeneca untuk membatalkan saman itu selepas mendengar hujahan kedua-dua pihak.
AstraZeneca rintis inisiatif kesaksamaan akses dalam perkhidmatan kesihatan
Portal mySihatPal menutup jurang akses kepada penyelesaian penjagaan kesihatan.
AstraZeneca tumpu kepada kepada penyakit jarang jumpa, teruskan pelaburan tempatan
AstraZeneca berhasrat menjadi pengupaya penyelesaian yang bekerjasama dalam aspek berbeza kepada pesakit.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
WEF2023: Tengku Zafrul bertemu lembaga pengarah AstraZeneca
Pertemuan itu berkisar mengenai potensi untuk AstraZeneca meluaskan operasi di Malaysia.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Mana-mana vaksin penggalak lebih baik dari tiada - Khairy
Walaupun Kementerian Kesihatan (KKM) menyarankan dos penggalak Pfizer atau AstraZeneca untuk memberi tambahan perlindungan yang terbaik, ada masyarakat yang masih meminta pilihan.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Pencipta AstraZeneca, GAVI terima Hadiah Keamanan Sunhak 2022
Pengiktirafan tersebut diberikan atas sumbangan signifikan yang diberikan mereka dalam membantu dunia menghadapi pandemik COVID-19.
KKM pantau semua vaksin COVID-19 - Dr Noor Hisham
KKM akan sentiasa memantau keselamatan semua vaksin COVID-19 yang telah didaftarkan secara bersyarat di Malaysia bagi menjamin keselamatan dan kesihatan rakyat.